keyword
MENU ▼
Read by QxMD icon Read
search

Shire pharmaceuticals

keyword
https://www.readbyqxmd.com/read/27783548/patterns-of-adherence-to-oral-atypical-antipsychotics-among-patients-diagnosed-with-schizophrenia
#1
Joanna P MacEwan, Felicia M Forma, Jason Shafrin, Ainslie Hatch, Darius N Lakdawalla, Jean-Pierre Lindenmayer
BACKGROUND: Poor medication adherence contributes to negative treatment response, symptom relapse, and hospitalizations in schizophrenia. Many health plans use claims-based measures like medication possession ratios or proportion of days covered (PDC) to measure patient adherence to antipsychotics. Classifying patients solely on the basis of a single average PDC measure, however, may mask clinically meaningful variations over time in how patients arrive at an average PDC level. OBJECTIVE: To model patterns of medication adherence evolving over time for patients with schizophrenia who initiated treatment with an oral atypical antipsychotic and, based on these patterns, to identify groups of patients with different adherence behaviors...
November 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27703782/ketamine-stimulating-antidepressant-treatment
#2
Gin S Malhi, Yulisha Byrow, Frederick Cassidy, Andrea Cipriani, Koen Demyttenaere, Mark A Frye, Michael Gitlin, Sidney H Kennedy, Terence A Ketter, Raymond W Lam, Rupert McShane, Alex J Mitchell, Michael J Ostacher, Sakina J Rizvi, Michael E Thase, Mauricio Tohen
SUMMARY: The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations...
May 2016: BJPsych Open
https://www.readbyqxmd.com/read/27459651/antihyperlipidemic-medication-treatment-patterns-and-statin-adherence-among-patients-with-ascvd-in-a-managed-care-plan-after-release-of-the-2013-acc-aha-guideline-on-the-treatment-of-blood-cholesterol
#3
Brandon K Bellows, Cody J Olsen, Jennifer Voelker, Curtis Wander
BACKGROUND: The American College of Cardiology (ACC) and American Heart Association (AHA) released a new blood cholesterol treatment guideline in November 2013. It is unknown how the new recommendations have affected cholesterol medication use and adherence in a commercial health plan. OBJECTIVE: To evaluate the effect of the 2013 guideline release on antihyperlipidemic treatment patterns and statin adherence in patients with atherosclerotic cardiovascular disease (ASCVD) compared with a historical control group...
August 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27173784/%C3%A2-guanfacine-for-adhd-in-children-and%C3%A2-adolescents
#4
(no author information available yet)
Prolonged-action ▼guanfacine (Intuniv-Shire Pharmaceuticals Ltd) is a non-stimulant drug that has recently been licensed in Europe for the management of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years for whom stimulants are unsuitable.(1) The company suggests that it has a unique mechanism of action in ADHD, providing improvement in core symptoms within 3 weeks with once-daily flexible dosing.(2) Here we review the evidence on the efficacy and safety of guanfacine in ADHD and consider whether it offers any advantages over other therapeutic options...
May 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/25951927/release-of-5-aminosalicylic-acid-5-asa-from-mesalamine-formulations-at-various-ph-levels
#5
Adeyinka Abinusawa, Srini Tenjarla
INTRODUCTION: Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon. In this study, we investigate the release of 5-ASA from available oral mesalamine formulations in physiologically relevant pH conditions. METHODS: Release of 5-ASA from 6 mesalamine formulations (APRISO®, Salix Pharmaceuticals, Inc., USA; ASACOL® MR, Procter & Gamble Pharmaceuticals UK Ltd...
May 2015: Advances in Therapy
https://www.readbyqxmd.com/read/25021571/pwe-085%C3%A2-audit-of-outcomes-of-a-managed-5-asa-switching-program
#6
N Taylor, D Chan, J Bowey, F Cummings
INTRODUCTION: 5-aminosalicylic acid (5-ASA) preparations are used to induce and maintain remission in ulcerative colitis (UC). The cost of the recommended maintenance dose for oral 5ASA preparations varies from 86p and 208p per day (MIMMS 2011). Switching to cheaper 5ASAs has been suggested as a possible drug cost saving. The BNF states that preparations are not interchangeable but with little direct evidence to support this statement. The aim of this pilot study is to gain preliminary data on a primary care based 5ASA switching programme...
June 2014: Gut
https://www.readbyqxmd.com/read/25021450/ptu-162%C3%A2-the-epidemiology-clinicopathological-characteristics-nd-outcomes-of-gists-in-the-north-east-of-england-over-a-five-year-period
#7
Mj Friel, Y Vishwanath, H Wescott, N Wadd, A Dhar
INTRODUCTION: Gastrointestinal stromal tumours (GISTs) are rare mesenchymal tumours of the gastrointestinal tract. In recent years there is increasing focus on immunohistochemistry biomarkers and targeted Imatinib therapy for treatment, but there is little data from the UK on factors that influence outcome. METHODS: We reviewed clinical, pathological, treatment strategies, follow-up and outcome data in all patients with GISTs at our regional multidisciplinary cancer group between Jan 2008 and Dec 2012...
June 2014: Gut
https://www.readbyqxmd.com/read/24992513/guanfacine-extended-release-for-the-treatment-of-attention-deficit-hyperactivity-disorder-in-children-and-adolescents
#8
REVIEW
Daniel F Connor, Amy F T Arnsten, Geraldine S Pearson, Gabriella F Greco
INTRODUCTION: Guanfacine extended release (GXR) is a selective α(2A)-adrenoreceptor agonist originally developed as an antihypertensive agent and now FDA approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) as monotherapy and as adjunctive to psychostimulants in children and adolescents 6-17 years old. AREAS COVERED: Search of the PubMed and PsycInfo databases from 1990 to 2014 using the search term 'guanfacine'. Studies selected for review were either controlled or open trials of guanfacine or GXR...
August 2014: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/24113146/what-place-for-lisdexamfetamine-in-children-and-adolescents-with-adhd
#9
(no author information available yet)
Attention deficit hyperactivity disorder (ADHD) is the commonest behavioural disorder in the UK, affecting 2-5% of school-aged children and young people.(1) Guidelines from the National Institute for Health and Care Excellence (NICE) state that medication is not indicated as first-line treatment for school-age children and young people with ADHD, but should be reserved for those with severe symptoms and impairment, or those with moderate levels of impairment who have refused non-drug interventions, or those whose symptoms have not responded sufficiently to parent-training/education programmes or group psychological treatment...
October 2013: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/22565161/once-daily-mmx-%C3%A2-mesalamine-for-endoscopic-maintenance-of-remission-of-ulcerative-colitis
#10
RANDOMIZED CONTROLLED TRIAL
Geert D'Haens, William J Sandborn, Karen Barrett, Ian Hodgson, Paul Streck
OBJECTIVES: Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line maintenance therapy. To improve treatment adherence, a mesalamine formulation that can be administered once-daily, MMX(®) mesalamine (Lialda; Shire Pharmaceuticals LLC, Wayne, PA), was developed. This study was conducted to determine the efficacy and safety of once-daily MMX mesalamine compared with twice-daily delayed-release mesalamine (Asacol; Warner Chilcott, Dublin, Ireland) for maintaining endoscopic remission in patients with UC...
July 2012: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/22457410/pre-existing-oral-contrast-from-lanthanum-carbonate-a-confounding-factor-in-ct-mesenteric-angiography
#11
M D Bull, R Shrimanker, M R M Thomas, C J Mulgrew
A 69-year-old male was referred from the renal unit to radiology for investigation of bleeding per rectum. A CT mesenteric angiogram was performed. However, it was noted on the pre-contrast images that the large bowel contained positive oral contrast media. The procedure was abandoned as it would have been difficult to see extravasation of intravenous contrast from a bleeding point in the large bowel. The initial belief was that either the patient had been given oral contrast by ward staff on the assumption that it would be needed, or had had a recent radiological study requiring contrast, which was still present...
April 2012: British Journal of Radiology
https://www.readbyqxmd.com/read/22391789/issues-and-challenges-of-subvisible-and-submicron-particulate-analysis-in-protein-solutions
#12
Thomas M Scherer, Stephenie Leung, Laura Owyang, Steven J Shire
The analysis of particulates has been a longstanding challenge in biopharmaceutical drug product development and quality control because the active constituents themselves may form particulate matter as a degradation product that may be difficult to quantify. These analytical challenges were met with success as long as the definition of particulate matter remained well within the capabilities of the instruments and methods used to measure it. The current testing as per USP <788> for parenterals at ≤100 mL stipulates that the sample "passes" the test if the average number of particles present does not exceed 6,000 per container at ≥10 μm and does not exceed 600 per container at ≥25 μm...
June 2012: AAPS Journal
https://www.readbyqxmd.com/read/22052104/p-o-p-a-study-prevention-of-postoperative-abdominal-adhesions-by-icodextrin-4-solution-after-laparotomy-for-adhesive-small-bowel-obstruction-a-prospective-randomized-controlled-trial
#13
RANDOMIZED CONTROLLED TRIAL
Fausto Catena, Luca Ansaloni, Salomone Di Saverio, Antonio D Pinna
BACKGROUND: Adhesive small bowel obstruction (ASBO) is an important cause of hospital admission, is associated with significant morbidity and mortality, and therefore is a substantial burden for healthcare systems worldwide. Icodextrin 4% solution (Adept, Shire Pharmaceuticals, UK) is a high-molecular-weight a-1,4 glucose polymer approved in Europe for use as intraoperative lavage and postoperative instillation to reduce the occurrence of post-surgery intra-abdominal adhesions. The present clinical study aimed to evaluate the safety and effectiveness of icodextrin 4% in decreasing the incidence, extent, and severity of adhesions in patients after abdominal surgery for ASBO...
February 2012: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/21831905/what-role-for-prucalopride-in-constipation
#14
REVIEW
(no author information available yet)
▾Prucalopride (Resolor - Shire Pharmaceuticals Ltd) is licensed, only in women, for symptomatic treatment of chronic constipation when laxatives fail to provide adequate relief. It is promoted as being "effective in helping to restore normal bowel movements and alleviating a broad range of constipation symptoms in women." Here we review the evidence for prucalopride and consider the drug's place as a treatment for chronic constipation.
August 2011: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/21183129/advances-in-the-treatment-of-attention-deficit-hyperactivity-disorder-a-guide-for-pediatric-neurologists
#15
REVIEW
Sharon B Wigal, Stephanie Chae, Avni Patel, Robin Steinberg-Epstein
The purpose of this article is to assist pediatric neurologists in practice and in training to better understand and distinguish between several of the most commonly prescribed treatments for attention-deficit/hyperactivity disorder (ADHD) in school-aged children. Among the various pharmacotherapies available for ADHD, 4 specific medications will be reviewed: oral release osmotic system methylphenidate hydrochloride (CON; Concerta, McNeil Pharmaceuticals), lisdexamfetamine dimesylate (LDX; Vyvanse, Shire Pharmaceuticals), atomoxetine (ATX; Strattera, Eli Lilly), and guanfacine extended-release (GXR; Intuniv, Shire Pharmaceuticals)...
December 2010: Seminars in Pediatric Neurology
https://www.readbyqxmd.com/read/21098011/long-term-treatment-with-lanthanum-carbonate-reduces-mineral-and-bone-abnormalities-in-rats-with-chronic-renal-failure
#16
Stephen Damment, Roger Secker, Victor Shen, Victor Lorenzo, Mariano Rodriguez
BACKGROUND: Lanthanum carbonate (FOSRENOL(®), Shire Pharmaceuticals) is an effective non-calcium, non-resin phosphate binder for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). In this study, we used a rat model of chronic renal failure (CRF) to examine the long-term effects of controlling serum phosphorus with lanthanum carbonate treatment on the biochemical and bone abnormalities associated with CKD-mineral and bone disorder (CKD-MBD). METHODS: Rats were fed a normal diet (normal renal function, NRF), or a diet containing 0...
June 2011: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/21088944/in-vitro-characterization-of-5-aminosalicylic-acid-release-from-mmx-mesalamine-tablets-and-determination-of-tablet-coating-thickness
#17
Srini Tenjarla, Adeyinka Abinusawa
INTRODUCTION: Substantial variability in gastrointestinal pH is observed in patients with ulcerative colitis (UC). We characterized the effect of pH on 5-aminosalicylic acid (5-ASA) release from MMX mesalamine tablets (Shire Pharmaceuticals Inc., Wayne, PA, USA), examined thickness/uniformity of tablet film coatings, and explored the influence of simulating altered gastrointestinal motility. METHODS: Nondestructive, three-dimensional, terahertz pulse imaging (TPI) was used to characterize the film coating of three lots of MMX mesalamine tablets (n=36)...
January 2011: Advances in Therapy
https://www.readbyqxmd.com/read/20821382/factors-affecting-the-viscosity-in-high-concentration-solutions-of-different-monoclonal-antibodies
#18
COMPARATIVE STUDY
Sandeep Yadav, Steven J Shire, Devendra S Kalonia
The viscosity profiles of four different IgG(1) molecules were studied as a function of concentration at pH 6.0. At high concentrations, MAb-H and -A showed significantly higher viscosities as compared to MAb-G and -E. Zeta Potential (ξ) measurements showed that all the IgG(1) molecules carried a net positive charge at this pH. MAb-G showed the highest positive zeta potential followed by MAb-E, -H, and -A. A consistent interpretation of the impact of net charge on viscosity for these MAbs is not possible, suggesting that electroviscous effects cannot explain the differences in viscosity...
December 2010: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/20564689/ief-pattern-classification-derived-criteria-for-the-identification-of-epoetin-delta-in-urine
#19
Séverine Lamon, Julien Boccard, Pierre-Edouard Sottas, Nicolas Glatz, Grégoire Wuerzner, Neil Robinson, Martial Saugy
Epoetin-delta (Dynepo Shire Pharmaceuticals, Basing stoke, UK) is a synthetic form of erythropoietin (EPO) whose resemblance with endogenous EPO makes it hard to identify using the classical identification criteria. Urine samples collected from six healthy volunteers treated with epoetin-delta injections and from a control population were immuno-purified and analyzed with the usual IEF method. On the basis of the EPO profiles integration, a linear multivariate model was computed for discriminant analysis. For each sample, a pattern classification algorithm returned a bands distribution and intensity score (bands intensity score) saying how representative this sample is of one of the two classes, positive or negative...
June 2010: Electrophoresis
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"